Reviewing Osmotica Pharmaceuticals plc (OSMT)’s and OHR Pharmaceutical Inc. (NASDAQ:OHRP)’s results

Osmotica Pharmaceuticals plc (NASDAQ:OSMT) and OHR Pharmaceutical Inc. (NASDAQ:OHRP), both competing one another are Biotechnology companies. We will compare their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Osmotica Pharmaceuticals plc 274.34M 1.50 6.40M -0.13 0.00
OHR Pharmaceutical Inc. N/A 0.00 13.24M -0.22 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Osmotica Pharmaceuticals plc and OHR Pharmaceutical Inc.

Profitability

Table 2 has Osmotica Pharmaceuticals plc and OHR Pharmaceutical Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Osmotica Pharmaceuticals plc -2.33% 0% 0%
OHR Pharmaceutical Inc. 0.00% -62.7% -54.6%

Liquidity

1.3 and 1.1 are the respective Current Ratio and a Quick Ratio of Osmotica Pharmaceuticals plc. Its rival OHR Pharmaceutical Inc.’s Current and Quick Ratios are 5.5 and 5.5 respectively. OHR Pharmaceutical Inc. has a better chance of clearing its pay short and long-term debts than Osmotica Pharmaceuticals plc.

Insider & Institutional Ownership

Roughly 37% of Osmotica Pharmaceuticals plc shares are held by institutional investors while 14.6% of OHR Pharmaceutical Inc. are owned by institutional investors. 41.8% are Osmotica Pharmaceuticals plc’s share held by insiders. Insiders Competitively, held 8.91% of OHR Pharmaceutical Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Osmotica Pharmaceuticals plc -0.38% -11% 0% 0% 0% -3.68%
OHR Pharmaceutical Inc. -5.33% -32.38% -25.58% -34.41% -90.21% -92.37%

For the past year Osmotica Pharmaceuticals plc’s stock price has smaller decline than OHR Pharmaceutical Inc.

Summary

On 7 of the 9 factors Osmotica Pharmaceuticals plc beats OHR Pharmaceutical Inc.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.